ArticleJournal of psychiatric research2026
Understanding and characterizing the higher rates of medical comorbidities in serious mental illness.
Article in Journal of psychiatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Individuals with serious mental illness (SMI) contend with medical comorbidities like hypertension, lowering their life expectancies. Here we evaluated these comorbidities in the Genomic Psychiatry Cohort, a large, diverse sample of subjects with SMI and controls. We also assessed the relationship of these illnesses with factors such as ancestry. Participants were sorted into one of three groups: 1) schizophrenia and schizoaffective disorder-depressed type (SZ, n = 8188), 2) bipolar with and without psychosis and schizoaffective disorder-bipolar type (BD, n = 5577) and 3) controls (CON, n = 10,850). Logistic regression models provided the odds of subjects endorsing heart problems, hypertension, high blood sugar, high cholesterol, and cancer compared to CONs. Similar models were used to evaluate the effects of probable alcohol use disorder (pAUD), probable tobacco use disorder (pTUD), ancestry, and sex. Both SZ and BD had higher odds of all five comorbidities compared to CONs, with OR ranging between 1.61 and 2.38 for SZ and 2.08 to 3.14 for BD (p < 0.0033). Having both SMI and pAUD was associated with higher odds of heart problems, hypertension, and cancer, though for pTUD this association held true for heart problems and cancer in SZ only (p < 0.0033). When comparing African-ancestry (AA) and European-ancestry (EA), hypertension and high blood sugar impacted AA with SMI more, though high cholesterol and cancer impacted EA with SMI more. Our findings suggest that SZ and BD are associated with higher rates of medical comorbidities, and factors such as pAUD, pTUD, and ancestry may be implicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.